Liver Cancer, Ototoxicity
Conditions
Keywords
ototoxicity, childhood hepatoblastoma, stage I childhood liver cancer, stage II childhood liver cancer, stage III childhood liver cancer
Brief summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as sodium thiosulfate, may protect normal cells from the side effects of chemotherapy. It is not yet known whether giving sodium thiosulfate is effective in reducing hearing damage caused by cisplatin in treating young patients with liver cancer. PURPOSE: This randomized phase III trial is studying how well sodium thiosulfate works to decrease hearing loss caused by cisplatin in treating young patients with stage I, stage II, or stage III childhood liver cancer.
Detailed description
OBJECTIVES: Primary * To assess the efficacy of sodium thiosulfate (STS) to reduce the hearing impairment caused by cisplatin chemotherapy. Secondary * To carefully monitor any potential impact of STS on response to cisplatin and survival. * To assess the short- and long-term tolerability of the combination of STS and cisplatin * To prospectively evaluate and validate biological, radiological and pathological features of standard-risk hepatoblastoma for future risk adapted management * To investigate the effect of STS on the formation of cisplatin-DNA adducts. * To prospectively collect patient DNA specifically for the analysis of possible genetic factors that may contribute to the development of treatment-related ototoxicity and nephrotoxicity OUTLINE: This is a multicenter study. Patients are stratified according to country, median age (\< 15 months vs ≥ 15 months), and PRETEXT tumor classification (I vs II vs III). Patients are randomized to 1 of 2 treatment arms. * Arm I (Neoadjuvant and adjuvant cisplatin): Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. * Arm II (Neoadjuvant and adjuvant cisplatin and sodium thiosulphate): Patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (beginning 6 hours after completion of cisplatin) on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (as in neoadjuvant therapy) on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity. Patients undergo blood collection and tumor biopsies periodically for biological and pharmacological studies consisting of biomarker analysis, gene expression profiling, IHC, proteomic analysis, and gene rearrangement analysis. Patients undergo auditory evaluations at baseline, and at the completion of study treatment or at an age of at least 3.5 years to measure ototoxicity and hearing impairment. After completion of study treatment, patients are followed periodically for at least 5 years.
Interventions
DRUGcisplatin
DRUGsodium thiosulfate
Sponsors
Childhood Liver Tumours Strategy Group - SIOPEL
University of Birmingham
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Months to 18 Years
Healthy volunteers
No
Inclusion criteria
Inclusion Histologically confirmed newly diagnosed hepatoblastoma * Standard risk hepatoblastoma (Pretext I,II,III) * Age ≤ 18 years and \> 1 month * Written informed consent and national/local ethics committee and regulatory approval * Centre/country willing and able to organise audiometry at the minimum required quality standard and to provide the contact details of the Consultant Audiologist or Ear Nose and Throat Surgeon who will take the responsibility for seeing that this is done * Ability to comply with requirements for submission of material for central review * For females of child-bearing potential, a negative pregnancy test prior to study treatment is required. * Any patient who is of reproductive age should agree to use adequate contraception for the duration of the trial. Exclusion: High risk hepatoblastoma * Hepatocellular carcinoma * Treatment starting more than 15 days from written biopsy report * Abnormal renal function * Any previous chemotherapy * Recurrent disease * Previous hypersensitivity to STS * Patient unable to follow the protocol for any reason
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Brock grade ≥ 1 hearing loss | End of trial treatment or at an age of 3.5 years, whichever is later | To investigate if the administration of sodium thiosulfate simultaneously with the administration of Cisplatin significantly reduces the hearing impairment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete resection | Within 2 weeks after surgery. | Total macroscopic removal of the tumour as reported by the surgeon and pathologist. In case of any doubt the lack of residual tumour must be confirmed with imaging studies performed |
| Complete remission | End of trial treatment | Lack of evidence of residual disease and normal (for age) alpha-foetal protein (AFP). To establish a complete remission all of the following requirements must be fulfilled: * No evidence of tumour intra-abdominally: negative abdominal (including hepatic) ultrasound or CT scan or Magnetic resonance imaging * No evidence of metastases: clear chest X-ray (PA and lateral) for non-metastatic patients. (Normal lung CT scan for patients with lung metastasis at diagnosis, who are high-risk by definition and not treated according to SIOPEL 6). * Serum AFP level either normal or compatible with age for at least 4 weeks after normalisation. |
| Event-free survival (EFS) | Until first event or up to 5 years | Calculated from the time of randomisation to the first of the following events: progression, relapse, secondary primary malignancy or death. |
| Response to preoperative chemotherapy | Following completion of preoperative chemotherapy | Defined as: Complete response (CR): no evidence of disease and normal serum AFP value (for age). Partial response (PR): any tumour volume shrinkage associated with a decreasing serum AFP value, \> 1 log below the original measurement. Stable disease (SD): no tumour volume change and no change, or \< 1 log fall of the serum AFP concentration. Progressive disease (PD): unequivocal increase in 1 or more dimensions and/or any unequivocal increase of the serum AFP concentration (three successive 1-2 weekly determinations) even without clinical (physical and/or radiological) evidence of tumour re-growth. |
| Toxicity as graded by CTCAE v 3.0 | 30 days post treatment | Adverse drug reactions are defined as adverse events, which are possibly, probably or definitely related to the trial treatment. They will be assessed according to NCI CTCAE v 3.0. |
| Long-term renal clearance | Until event or up to 5 years | By clearance method either EDTA, iohexol or inulin. |
| Feasibility of central audiology review | End of trial treatment or at an age of 3.5 years, whichever is later | The feasibility of central review |
| Overall survival (OS) | Until event or up to 5 years | Calculated from the time of randomisation to death. |
Countries
United Kingdom
Outcome results
None listed